New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
08:38 EDTROSGRosetta Genomics announces its cancer test received provider status
Rosetta Genomics announces the Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services, a subsidiary of Highmark. This test for the identification of the tumor origin in Cancer of Unknown or Uncertain Primary is now available to eligible Highmark Health Services members as an in-network service based on the individual member's benefits.
News For ROSG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 26, 2015
09:03 EDTROSGRosetta announces selection of first pilot project grant under MCC alliance
Rosetta Genomics (ROSG) announces the selection of the first project grant under its strategic alliance with Moffitt Cancer Center. The funded project is titled, “miRNAs as Determinants and Predictors of Ibrutinib Resistance in Mantle Cell Lymphoma.” The project will be led by Jianguo Tao, M.D., Ph.D., a renowned hematopathologist and physician-scientist at the Molecular and Chemical Biology Program at Moffitt, and Bijal Shah, M.D., an oncologist in the Experimental Therapeutic Program at Moffitt. MCL is an aggressive B-cell lymphoma. Ibrutinib, a blockbuster pharmaceutical marketed by Pharmacyclics (PCYC) under the brand name of IMBRUVICA, is a novel Bruton's tyrosine kinase inhibitor that received U.S. Food and Drug Administration approval for the treatment of MCL in 2014, with high response rates reported in patients with MCL. However, many MCL patients who initially show a partial or complete response to ibrutinib, eventually develop ibrutinib-acquired drug resistance accompanied by fulminant progression and accelerated mortality. Studies conducted by Drs. Tao and Shah have suggested that microRNAs play a role in the development of resistance to ibrutinib. The goal of this funded project is to further explore the role and underlying molecular mechanism of microRNAs in ibrutinib resistance in MCL, for development of microRNA-based predictive biomarkers for ibrutinib therapy, as well as for a rational design to overcome drug resistance.
May 14, 2015
08:50 EDTROSGRosetta Genomics launches two assays for bladder cancer
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use